

Clinical Trial Protocol

Iranian Registry of Clinical Trials

11 Sep 2026

Evaluation of the effect of oral eplerenone in the management of Acute Central Serous Chorioretinopathy

Protocol summary

Study aim

Evaluation of the effect of oral eplerenone in the management of Acute Central Serous Chorioretinopathy

Design

A clinical trial with a control group, with parallel groups, single-blind, randomized, phase 3 on about 36 patients.

Settings and conduct

Patients who refer to Baqiyatullah Clinic due to acute central serous chorioretinopathy will be included in the study according to the entry and exit criteria. Patients will be randomly divided into intervention and control groups. At first, each patient will undergo visual acuity evaluation and SD-OCT and clinical examinations. The intervention group treated with eplerenone and the control group will receive Eye vit plus tablets. Patients will be followed up in 1, 2, 3 months after the start of treatment by measuring BCVA and SD-OCT. Whenever the disease improves during the treatment period, the drug will be discontinued. Then the measured data in two groups of case and control are analyzed and compared with appropriate statistical tests.

Participants/Inclusion and exclusion criteria

Acute central serous chorioretinopathy before twelve weeks Acute central serous chorioretinopathy for the first time

Intervention groups

Intervention group: Patients in the case group will be treated with eplerenone oral tablets, at the rate of 50 mg per day for 12 weeks. Follow-up of patients in 1, 2, 3 months after the start of treatment will be done by measuring BCVA and SD-OCT. Whenever the disease improves during the treatment period, the drug will be discontinued. Control group: Patients of the case group will be treated with eye vit plus oral tablets, one tablet daily for 12 weeks. The follow-up of the patients will be the same as the intervention group.

Main outcome variables

Primary outcome measures will include comparison of BCVA, SD-OCT and clinical examinations between

treatment and control groups and at all time points.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20220423054621N1**

Registration date: **2024-06-24, 1403/04/04**

Registration timing: **prospective**

Last update: **2024-06-24, 1403/04/04**

Update count: **0**

Registration date

2024-06-24, 1403/04/04

Registrant information

Name

mona alvandimanesh

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 921 241 8042

Email address

monaalvandimanesh@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2024-06-29, 1403/04/09

Expected recruitment end date

2024-09-04, 1403/06/14

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty	company has been asked to make a placebo in the same packaging as the drug under study) and the patients and also the person evaluating the consequences of the status of assignment to the treatment groups And they will not know the hypothesis of the study.
Scientific title Evaluation of the effect of oral eplerenone in the management of Acute Central Serous Chorioretinopathy	Placebo Not used
Public title Evaluation of the effect of oral eplerenone in the management of Acute Central Serous Chorioretinopathy	Assignment Parallel
Purpose Treatment	Other design features
Inclusion/Exclusion criteria Inclusion criteria: Diagnosis of acute central serous chorioretinopathy before twelve weeks Diagnosis of acute central serous chorioretinopathy for the first time Exclusion criteria: Chronic CSCR (duration of visual symptoms more than 12 weeks) Recurrent CSCR (patients with a history of one or more previous CSCR attacks) Choroidal neovascularization (CNV) detected by FA, ICGA, or OCT angiography (OCT-A) Any treatment for retinal disease (including intravitreal injections, photodynamic therapy, laser photocoagulation, vitrectomy) History of other retinal disorders (including age-related macular degeneration, choroidal neovascularization, diabetic retinopathy, uveitis, or pathological myopia) The presence of any other systemic disease for which eplerenone is contraindicated (such as severe renal, cardiac or hepatic failure, pregnancy, baseline serum potassium more than 0.5 mEq/L simultaneous administration of potassium-sparing diuretics, potassium supplements, inhibitors angiotensin converting enzyme or angiotensin receptor blockers)	Secondary Ids empty
Age From 18 years old	Ethics committees 1 Ethics committee Name of ethics committee Ethics committee of baghiatallah University of Medical Sciences Street address Vanak Sq Mollasadra Ave City Tehran Province Tehran Postal code 1435915371
Gender Both	Approval date 2024-01-13, 1402/10/23 Ethics committee reference number IR.BMSU.BAQ.REC.1402.088
Phase 3	Health conditions studied 1 Description of health condition studied Acute Central Serous Chorioretinopathy ICD-10 code H35.7 ICD-10 code description Separation of retinal layers
Groups that have been masked • Participant • Outcome assessor • Data analyser	Primary outcomes 1 Description Best corrected visual acuity (BCVA) Timepoint At the beginning of the study, one month, two months and three months later Method of measurement Tumbling E" eye chart
Sample size Target sample size: 20	2 Description
Randomization (investigator's opinion) Randomized	
Randomization description Random allocation will be done using the random blocking method (blocks of four). The possible blocks are as follows: 1- AABB, 2- ABAB, 3- BABA, 4- BBAA, 5- BAAB, 6- ABBA. In this step, numbers (1 to 6) will be randomly selected using the table of random numbers. and this work is repeated 10 times until the sample volume is reached.	
Blinding (investigator's opinion) Single blinded	
Blinding description The drugs of the two groups will be similar in terms of shape, color and packaging (the pharmaceutical	

Central Macular Thickness (CMT)

Timepoint

At the beginning of the study, one month, two months and three months later

Method of measurement

Use of SD-OCT device

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Patients in the case group will be treated with eplerenone oral tablets, at the rate of 50 mg per day for 12 weeks. Follow-up of patients in 1, 2, 3 months after the start of treatment will be done by measuring BCVA and SD-OCT. Whenever the disease improves during the treatment period, the drug will be discontinued.

Category

Treatment - Drugs

2

Description

Control group: The patients of the case group will be treated with eye vit plus oral tablets (OPD Pharma), one pill per day for 12 weeks. Follow-up of patients in 1, 2, 3 months after the start of treatment will be done by measuring BCVA and SD-OCT. Whenever the disease improves during the treatment period, the drug will be discontinued.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Baqiyat Allah Clinic

Full name of responsible person

Mona Alvandimanesh

Street address

Baqiyatullah Al-Azam Hospital ,Mulla Sadra St. ,
Vanak Square

City

Tehran

Province

Tehran

Postal code

1435915371

Phone

+98 21 85554

Email

Dr.Samadinia@bmsu.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Bagheiat-allah University of Medical Sciences

Full name of responsible person

Dr Nematollah Jonaidi

Street address

Baqiyatullah Al-Azam Hospital, Mulla Sadra St., Vanak
Square

City

Tehran

Province

Tehran

Postal code

1435915371

Phone

+98 21 85554

Email

dr.samadinia@bmsu.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Bagheiat-allah University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Bagheiat-allah University of Medical Sciences

Full name of responsible person

Mona Alvandimanesh

Position

Ophthalmology Resident

Latest degree

Medical doctor

Other areas of specialty/work

Ophthalmology

Street address

Baqiyatullah Al-Azam Hospital, Mulla Sadra St., Vanak
Square

City

Tehran

Province

Tehran

Postal code

1435915371

Phone

+98 921 241 8042

Email

Monaalvandimanesh@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Bagheiat-allah University of Medical Sciences

Full name of responsible person

Mona Alvandimanesh

Position

Ophthalmology Resident

Latest degree

Medical doctor

Other areas of specialty/work

Ophthalmology

Street address

Baqiyatullah Al-Azam Hospital, Mulla Sadra St., Vanak Square

City

Tehran

Province

Tehran

Postal code

1435915371

Phone

+98 921 241 8042

Email

Monaalvandimanesh@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Bagheiat-allah University of Medical Sciences

Full name of responsible person

Mona Alvandimanesh

Position

Ophthalmology Resident

Latest degree

Medical doctor

Other areas of specialty/work

Ophthalmology

Street address

Baqiyatullah Al-Azam Hospital, Mulla Sadra St., Vanak

Square

City

Tehran

Province

Tehran

Postal code

1435915371

Phone

+98 921 241 8042

Email

Monaalvandimanesh@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Information about the main outcome can be shared.

When the data will become available and for how long

Access to the data is possible immediately after the result is determined

To whom data/document is available

The data will be available to researchers

Under which criteria data/document could be used

The information can be used for further study and research

From where data/document is obtainable

Responsible for the project's scientific information
monaalvandimanesh@gmail.com

What processes are involved for a request to access data/document

After sending the request, the information will be available to the applicant within three days

Comments